MiNK Therapeutics receives Nasdaq delisting notice for failing to meet $1.00 bid price rule

MiNK Therapeutics, Inc.

Nasdaq notified MiNK on Aug 27, 2024 that it failed to regain compliance with the $1.00 minimum bid price within the 180-day grace period ending Aug 26, 2024.
Common stock (INKT) is now subject to potential delisting from Nasdaq.
MiNK intends to request a hearing before the Nasdaq Hearings Panel, which will stay any delisting action pending the process.
No assurance that the Panel will allow continued listing or that compliance can be demonstrated within any extension granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.